In t(8;21) AML cells expressing the fusion oncoprotein AML1–ETO (eight-twenty-one), targeted therapies such as histone deacetylase inhibitors (HDACis) are warranted. This evidence concerns the gene RUNX1 and acute myeloid leukemia.